News
TECH
78.67
+1.37%
1.06
Weekly Report: what happened at TECH last week (0715-0719)?
Weekly Report · 4d ago
BIO-TECHNE CORP <TECH.O>: LEERINK PARTNERS CUTS TARGET PRICE TO $90 FROM $95
Reuters · 07/18 10:40
Bio-Techne's (NASDAQ:TECH) 8.6% CAGR outpaced the company's earnings growth over the same five-year period
Bio-Techne Corporation's share price is down 6.6% in the last year. The company has grown its earnings per share at 9.9% a year over the last five years. The share price of the company is up 48% in five years, but less than the market return. Over the longer term, the company's fundamentals are better than the share price.
Simply Wall St · 07/15 10:43
Weekly Report: what happened at TECH last week (0708-0712)?
Weekly Report · 07/15 09:14
These are the stocks with the highest increase in short interest within life sciences and diagnostics - Baird
Exact Sciences Corp. Had the highest percentage increase in shares sold short within the life sciences and diagnostics sector at the end of June vs. The prior month. Five stocks within the sector saw more than 10% increase in short interest through May. Twist Bioscience had the lowest percentage of short interest in the sector.
Seeking Alpha · 07/12 18:30
GMAB or TECH: Which Is the Better Value Stock Right Now?
NASDAQ · 07/09 15:40
Weekly Report: what happened at TECH last week (0701-0705)?
Weekly Report · 07/08 09:15
Weekly Report: what happened at TECH last week (0624-0628)?
Weekly Report · 07/01 09:15
Should Weakness in Bio-Techne Corporation's (NASDAQ:TECH) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?
Simply Wall St · 06/27 10:45
RBC Capital Reaffirms Their Hold Rating on Bio-Techne (TECH)
TipRanks · 06/25 01:45
Weekly Report: what happened at TECH last week (0617-0621)?
Weekly Report · 06/24 09:15
Analysts Offer Insights on Healthcare Companies: Bio-Techne (TECH) and Medacta Group SA (OtherMEDGF)
TipRanks · 06/24 08:00
Analysts Anticipate RWL To Hit $103
NASDAQ · 06/21 10:24
Tracking Ron Baron's BAMCO Portfolio - Q1 2024 Update
Baron Capital's 13F stock portfolio value decreased slightly this quarter to $37.52B. Top five stakes include Tesla Motors, Gartner Inc, Arch Capital Group, and MSCI Inc. Stake increases in Red Rock Resorts and SiteOne Landscape, while stake decreases in Tesla Motors.
Seeking Alpha · 06/21 01:56
Weekly Report: what happened at TECH last week (0610-0614)?
Weekly Report · 06/17 09:14
Strategy To YieldBoost TECH From 0.4% To 6.4% Using Options
NASDAQ · 06/13 15:46
Weekly Report: what happened at TECH last week (0603-0607)?
Weekly Report · 06/10 09:15
When Should You Buy Bio-Techne Corporation (NASDAQ:TECH)?
Bio-Techne Corporation (NASDAQ:TECH) saw a significant share price rise of 25% in the past month. The company is trading above its peers in the Life Sciences industry. But could the stock still be trading at a relatively cheap price? We examine the company's valuation and outlook to see if it is still cheap.
Simply Wall St · 06/09 14:15
Weekly Report: what happened at TECH last week (0527-0531)?
Weekly Report · 06/03 09:15
SCALEREADY ANNOUNCES $20 MILLION G-REX® GRANT PROGRAM FOR THE ADVANCEMENT OF CELL AND GENE THERAPY (CGT) DEVELOPMENT AND MANUFACTURING
Reuters · 05/29 11:00
More
Webull provides a variety of real-time TECH stock news. You can receive the latest news about Bio-Techne Corp through multiple platforms. This information may help you make smarter investment decisions.
About TECH
Bio-Techne Corporation is a global life sciences company. The Company is engaged in providing tools and bioactive reagents for the research and clinical diagnostic communities. It operates through two segments: Protein Sciences and Diagnostics and Genomics. Its Protein Sciences segment develops and manufactures biological reagents used in all aspects of life science research, diagnostics and cell and gene therapy. This segment also includes proteomic analytical tools, both manual and automated, that offer researchers and pharmaceutical manufacturers efficient and streamlined options for automated western blot and multiplexed ELISA workflow. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for the regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits.